|
1
|
Warburg O: On the origin of cancer cells.
Science. 123:309–314. 1956. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cairns RA, Harris IS and Mak TW:
Regulation of cancer cell metabolism. Nat Rev Cancer. 11:85–95.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hakimi AA, Reznik E, Lee CH, Creighton CJ,
Brannon AR, Luna A, Aksoy BA, Liu EM, Shen R, Lee W, et al: An
integrated metabolic atlas of clear cell renal cell carcinoma.
Cancer Cell. 29:104–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Denkert C, Budczies J, Weichert W,
Wohlgemuth G, Scholz M, Kind T, Niesporek S, Noske A, Buckendahl A,
Dietel M and Fiehn O: Metabolite profiling of human colon
carcinoma-deregulation of TCA cycle and amino acid turnover. Mol
Cancer. 7:722008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang H, Wang L, Zhang H, Deng P, Chen J,
Zhou B, Hu J, Zou J, Lu W, Xiang P, et al: ¹H NMR-based metabolic
profiling of human rectal cancer tissue. Mol Cancer. 12:1212013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li B, Qiu B, Lee DS, Walton ZE, Ochocki
JD, Mathew LK, Mancuso A, Gade TP, Keith B, Nissim I and Simon MC:
Fructose-1,6-bisphosphatase opposes renal carcinoma progression.
Nature. 513:251–255. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta
R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS,
et al: Ferroptosis: An iron-dependent form of nonapoptotic cell
death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang WS, SriRamaratnam R, Welsch ME,
Shimada K, Skouta R, Viswanathan VS, Cheah JH, Clemons PA, Shamji
AF, Clish CB, et al: Regulation of ferroptotic cancer cell death by
GPX4. Cell. 156:317–331. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yang WS and Stockwell BR: Ferroptosis:
Death by lipid peroxidation. Trends Cell Biol. 26:165–176. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Skouta R, Dixon SJ, Wang J, Dunn DE, Orman
M, Shimada K, Rosenberg PA, Lo DC, Weinberg JM, Linkermann A and
Stockwell BR: Ferrostatins inhibit oxidative lipid damage and cell
death in diverse disease models. J Am Chem Soc. 136:4551–4556.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xie Y, Hou W, Song X, Yu Y, Huang J, Sun
X, Kang R and Tang D: Ferroptosis: Process and function. Cell Death
Differ. 23:369–379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lu SC: Glutathione synthesis. Biochim
Biophys Acta. 1830:3143–3153. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Bailey HH, Ripple G, Tutsch KD,
Arzoomanian RZ, Alberti D, Feierabend C, Mahvi D, Schink J, Pomplun
M, Mulcahy RT and Wilding G: Phase I study of continuous-infusion
L-S,R-buthionine sulfoximine with intravenous melphalan. J Natl
Cancer Inst. 89:1789–1796. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sakamoto K, Adachi Y, Komoike Y, Kamada Y,
Koyama R, Fukuda Y, Kadotani A, Asami T and Sakamoto JI: Novel
DOCK2-selective inhibitory peptide that suppresses B-cell line
migration. Biochem Biophys Res Commun. 483:183–190. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Winterbourn CC and Brennan SO:
Characterization of the oxidation products of the reaction between
reduced glutathione and hypochlorous acid. Biochem J. 326:87–92.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Winkler BS, DeSantis N and Solomon F:
Multiple NADPH-producing pathways control glutathione (GSH) content
in retina. Exp Eye Res. 43:829–847. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Patra KC and Hay N: The pentose phosphate
pathway and cancer. Trends Biochem Sci. 39:347–354. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Muñoz-Pinedo C, El Mjiyad N and Ricci JE:
Cancer metabolism: Current perspectives and future directions. Cell
Death Dis. 3:e2482012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Singh D, Arora R, Kaur P, Singh B, Mannan
R and Arora S: Overexpression of hypoxia-inducible factor and
metabolic pathways: Possible targets of cancer. Cell Biosci.
7:622017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Courtnay R, Ngo DC, Malik N, Ververis K,
Tortorella SM and Karagiannis TC: Cancer metabolism and the Warburg
effect: The role of HIF-1 and PI3K. Mol Biol Rep. 42:841–851. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Haase VH: The VHL tumor suppressor: Master
regulator of HIF. Curr Pharm Des. 15:3895–3903. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Satoh K, Yachida S, Sugimoto M, Oshima M,
Nakagawa T, Akamoto S, Tabata S, Saitoh K, Kato K, Sato S, et al:
Global metabolic reprogramming of colorectal cancer occurs at
adenoma stage and is induced by MYC. Proc Natl Acad Sci USA.
114:E7697–E7706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yuan M, Breitkopf SB, Yang X and Asara JM:
A positive/negative ion-switching, targeted mass spectrometry-based
metabolomics platform for bodily fluids, cells, and fresh and fixed
tissue. Nat Protoc. 7:872–881. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Soga T and Heiger DN: Amino acid analysis
by capillary electrophoresis electrospray ionization mass
spectrometry. Anal Chem. 72:1236–1241. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soga T, Ohashi Y, Ueno Y, Naraoka H,
Tomita M and Nishioka T: Quantitative metabolome analysis using
capillary electrophoresis mass spectrometry. J Proteome Res.
2:488–494. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Soga T, Igarashi K, Ito C, Mizobuchi K,
Zimmermann HP and Tomita M: Metabolomic profiling of anionic
metabolites by capillary electrophoresis mass spectrometry. Anal
Chem. 81:6165–6174. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bailey HH, Mulcahy RT, Tutsch KD,
Arzoomanian RZ, Alberti D, Tombes MB, Wilding G, Pomplun M and
Spriggs DR: Phase I clinical trial of intravenous L-buthionine
sulfoximine and melphalan: An attempt at modulation of glutathione.
J Clin Oncol. 12:194–205. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mehta S, Shelling A, Muthukaruppan A,
Lasham A, Blenkiron C, Laking G and Print C: Predictive and
prognostic molecular markers for cancer medicine. Ther Adv Med
Oncol. 2:125–148. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Dienstmann R, Rodon J and Tabernero J:
Biomarker-driven patient selection for early clinical trials. Curr
Opin Oncol. 25:305–312. 2013.PubMed/NCBI
|
|
31
|
Schmidt KT, Chau CH, Price DK and Figg WD:
Precision oncology medicine: The clinical relevance of
patient-specific biomarkers used to optimize cancer treatment. J
Clin Pharmacol. 56:1484–1499. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Terpstra M, Vaughan TJ, Ugurbil K, Lim KO,
Schulz SC and Gruetter R: Validation of glutathione quantitation
from STEAM spectra against edited 1H NMR spectroscopy at 4T:
Application to schizophrenia. MAGMA. 18:276–282. 2005. View Article : Google Scholar : PubMed/NCBI
|
